Sana Q1 net loss $107.5M; cash $311M after $189.8M financing; four trials on track for 2024

Sana Biotechnology, Inc.

2024-Q1 EPS reported -$0.49

Net loss GAAP $107.5M ($0.49/share) vs $82.1M ($0.43) YoY; adjusted net loss $69.5M ($0.32).
Cash, equivalents & securities $311.1M (Dec 2023: $205.2M); boosted by $189.8M gross equity offering in Feb 2024.
Non-GAAP operating cash burn $58.7M in Q1 vs $74.8M YoY; full-year 2024 cash burn guided below $200M.
Four ongoing clinical programs (SC291, SC262, UP421) across seven indications; initial data expected throughout 2024.
R&D expenses $56.4M, down 16% from $67.2M, reflecting 2023 strategic repositioning and headcount reduction.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sana Biotechnology, Inc. reported financial results for the quarter and year ended March 31, 2024.

Period: the quarter and year ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055673

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.